abstract |
[003611 The present invention relates to triterpene glycoside saponin-derived nadjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent nimmune-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently nthe favoured adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification nprotocols have hindered the clinical development of QS-7. A novel semi-synthetic method is nprovided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and nrelated analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and nclinical evaluation. |